Clinical Psychology Speaker Series: Ethics & Equity in Alzheimer’s Disease Biomarker Testing & Disclosure

April 11, 2025

9:30 am - 10:30 am

Psychology Building Room 35

Add to Calendar 2025-04-11 09:30:00 2025-04-11 10:30:00 Clinical Psychology Speaker Series: Ethics & Equity in Alzheimer’s Disease Biomarker Testing & Disclosure Join us for the Clinical Psychology Speaker Series with Dr. Annalise Rahman-Filipiak (Department of Psychiatry-Neuropsychology Section, University of Michigan Medical School)!This is a hybrid event. Join us in person in Psychology Building Room 35 (1835 Neil Ave., Columbus, OH, 43210) OR on Zoom (Meeting ID: 927 8539 9851 and Password: 112791).Title: Ethics and Equity in Alzheimer's Disease Biomarker Testing and DisclosureAbstract: Alzheimer’s disease (AD) and dementia of the Alzheimer’s type (DAT) disproportionately affects people of diverse racial-ethnic backgrounds; however, patients from these communities are diagnosed less often, less accurately, and later than Non-Hispanic white patients. Additionally, a lack of historical and current representation in AD research limits our ability to systematically study the complex and myriad social determinants driving these disparities. The recent development and rapid implementation of AD biomarkers present an opportunity for earlier and more accurate identification of those at risk for DAT, broadening the window for research, treatment, and planning in early stages of the disease. However, AD biomarker testing is associated with significant risks including psychological distress, stigma, and medicolegal discrimination, all of which already disproportionately impact participants from underserved communities. Thus, biomarker testing and disclosure of results must be conducted through the lens of both ethics and equity. Given our unique training, clinical psychologists and neuropsychologists are critical contributors to the burgeoning science of disclosure. About Dr. Rahman-Filipiak: Annalise Rahman-Filipiak is a clinical neuropsychologist and assistant professor with the Department of Psychiatry - Neuropsychology Section at the University of Michigan Medical School and the Michigan Alzheimer's Disease Research Center. Dr. Rahman-Filipiak's interests include culturally informed behavioral interventions to communicate Alzheimer’s disease biomarker results and reduce dementia risk. Psychology Building Room 35 OSU ASC Drupal 8 ascwebservices@osu.edu America/New_York public

2025-04-11 09:30:00 2025-04-11 10:30:00 Clinical Psychology Speaker Series: Ethics & Equity in Alzheimer’s Disease Biomarker Testing & Disclosure Join us for the Clinical Psychology Speaker Series with Dr. Annalise Rahman-Filipiak (Department of Psychiatry-Neuropsychology Section, University of Michigan Medical School)!This is a hybrid event. Join us in person in Psychology Building Room 35 (1835 Neil Ave., Columbus, OH, 43210) OR on Zoom (Meeting ID: 927 8539 9851 and Password: 112791).Title: Ethics and Equity in Alzheimer's Disease Biomarker Testing and DisclosureAbstract: Alzheimer’s disease (AD) and dementia of the Alzheimer’s type (DAT) disproportionately affects people of diverse racial-ethnic backgrounds; however, patients from these communities are diagnosed less often, less accurately, and later than Non-Hispanic white patients. Additionally, a lack of historical and current representation in AD research limits our ability to systematically study the complex and myriad social determinants driving these disparities. The recent development and rapid implementation of AD biomarkers present an opportunity for earlier and more accurate identification of those at risk for DAT, broadening the window for research, treatment, and planning in early stages of the disease. However, AD biomarker testing is associated with significant risks including psychological distress, stigma, and medicolegal discrimination, all of which already disproportionately impact participants from underserved communities. Thus, biomarker testing and disclosure of results must be conducted through the lens of both ethics and equity. Given our unique training, clinical psychologists and neuropsychologists are critical contributors to the burgeoning science of disclosure. About Dr. Rahman-Filipiak: Annalise Rahman-Filipiak is a clinical neuropsychologist and assistant professor with the Department of Psychiatry - Neuropsychology Section at the University of Michigan Medical School and the Michigan Alzheimer's Disease Research Center. Dr. Rahman-Filipiak's interests include culturally informed behavioral interventions to communicate Alzheimer’s disease biomarker results and reduce dementia risk.  Psychology Building Room 35 America/New_York public

Join us for the Clinical Psychology Speaker Series with Dr. Annalise Rahman-Filipiak (Department of Psychiatry-Neuropsychology Section, University of Michigan Medical School)!

This is a hybrid event. Join us in person in Psychology Building Room 35 (1835 Neil Ave., Columbus, OH, 43210) OR on Zoom (Meeting ID: 927 8539 9851 and Password: 112791).

Title: Ethics and Equity in Alzheimer's Disease Biomarker Testing and Disclosure

Abstract: Alzheimer’s disease (AD) and dementia of the Alzheimer’s type (DAT) disproportionately affects people of diverse racial-ethnic backgrounds; however, patients from these communities are diagnosed less often, less accurately, and later than Non-Hispanic white patients. Additionally, a lack of historical and current representation in AD research limits our ability to systematically study the complex and myriad social determinants driving these disparities. The recent development and rapid implementation of AD biomarkers present an opportunity for earlier and more accurate identification of those at risk for DAT, broadening the window for research, treatment, and planning in early stages of the disease. However, AD biomarker testing is associated with significant risks including psychological distress, stigma, and medicolegal discrimination, all of which already disproportionately impact participants from underserved communities. Thus, biomarker testing and disclosure of results must be conducted through the lens of both ethics and equity. Given our unique training, clinical psychologists and neuropsychologists are critical contributors to the burgeoning science of disclosure.

About Dr. Rahman-Filipiak: Annalise Rahman-Filipiak is a clinical neuropsychologist and assistant professor with the Department of Psychiatry - Neuropsychology Section at the University of Michigan Medical School and the Michigan Alzheimer's Disease Research Center. Dr. Rahman-Filipiak's interests include culturally informed behavioral interventions to communicate Alzheimer’s disease biomarker results and reduce dementia risk.

Events Filters:

Talk/Lecture

All Audiences